This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OREX Orexigen Therapeutics (OREX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Orexigen Therapeutics Stock (NASDAQ:OREX) 30 days 90 days 365 days Advanced Chart Get Orexigen Therapeutics alerts:Sign Up Key Stats Today's Range$0.22▼$0.3250-Day Range$0.22▼$0.2252-Week Range$0.17▼$3.81Volume3.74 million shsAverage Volume1.16 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read More Receive OREX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orexigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OREX Stock News HeadlinesOrexigen Therapeutics Stock Price HistoryJune 21, 2025 | investing.comAardvark Therapeutics, Inc. Announces Key Leadership Appointments to Enhance Scientific, Commercial, and Regulatory ExpertiseMay 21, 2025 | nasdaq.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 2 at 2:00 AM | Porter & Company (Ad)Aardvark Therapeutics Expands Management Team with Two Key HiresSeptember 11, 2024 | finance.yahoo.comTemporary Animal Adoption Center Opens In The Avenue At White MarshAugust 15, 2024 | msn.comXeno Biosciences Announces New CEO and FinancingApril 17, 2024 | businesswire.comOrexigen Tanks After-Hours on Obesity DataAugust 27, 2023 | thestreet.comRegulus Therapeutics Inc.: Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent UpdatesAugust 9, 2023 | finanznachrichten.deSee More Headlines OREX Stock Analysis - Frequently Asked Questions How were Orexigen Therapeutics' earnings last quarter? Orexigen Therapeutics, Inc. (NASDAQ:OREX) released its earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping the consensus estimate of ($2.13) by $0.78. The firm's revenue for the quarter was up 170.0% on a year-over-year basis. What other stocks do shareholders of Orexigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orexigen Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Arena Pharmaceuticals (ARNA), MannKind (MNKD), Novavax (NVAX), Bristol Myers Squibb (BMY), Rexahn Pharmaceuticals (REXN) and ImmunoGen (IMGN). Company Calendar Last Earnings11/13/2017Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:OREX CIK1382911 Webwww.orexigen.com Phone858-875-8600FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:OREX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orexigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orexigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.